Market's view on Alliance Pharma
Published on April 2024
- Stock watchers express concerns about the preliminary results publication delay to early May, which Alliance Pharma initially scheduled for 23 April 2024. The auditor, Deloitte LLP, needs more time to finalise its work.
- The delay marks a total of four weeks from the original schedule. Stock watchers are concerned this could signal deeper issues.
- There are discussions about the potential impact of current remittances from China and decreasing debt on the company’s performance.
- Speculations about the CMA sanctions and their possible dilution, and how these factors could make Alliance Pharma’s stock more interesting in the coming weeks.
- Stock watchers note that share prices are approaching a three-year low, which might indicate a significant risk for investors.
- Some stock watchers express distrust towards Deloitte LLP, suggesting the need for Alliance Pharma to change its accounting firm due to dissatisfaction with the current auditor.
- Discussions include the impact of the trading update for the fiscal year results, which were positive, and how potential dividend payments might influence the stock price, with projections varying based on whether dividends are reinstated.